acquisition
VISA INC. $215 is a buy. The company (New York symbol V; Conservative Growth Portfolio, Finance sector; Shares outstanding: 2.1 billion; Market cap: $451.5 billion; Price-to-sales ratio: 16.8; Dividend yield: 0.7%; TSINetwork Rating: Above Average; www.visa.com) has suspended is operations in Russia as a result of that country’s attack on Ukraine....
A: Anaergia, $13.74, symbol ANRG on Toronto (Shares outstanding: 24.3 million; Market cap: $777.3 million; www.anaergia.com), engages in equipment design, process engineering, equipment manufacturing, and project integration, financing and execution to handle municipal solid waste (MSW), wastewater and discarded agri-food.
The company converts the organic waste into clean water, fertilizer, and renewable natural gas.
Established in 2007, Anaergia was formed to bring European resource recovery and high solids anaerobic digestion technologies to North America....
The company converts the organic waste into clean water, fertilizer, and renewable natural gas.
Established in 2007, Anaergia was formed to bring European resource recovery and high solids anaerobic digestion technologies to North America....
In a miserable situation like the Russian invasion of Ukraine, it’s rare to hear good news. This past week, Russia carried out terror bombings of orphanages, maternity wards, hospitals and homes for the elderly. Meanwhile, some NATO members refused to close off Ukrainian airspace, or allow Ukraine’s neighbours to lend it their MIG jets....
ZIMMER BIOMET HOLDINGS INC., $120.77, symbol ZBH on New York, manufactures orthopedic reconstructive implants and surgical equipment for orthopedic surgeries. Zimmer has the largest market share for reconstructive implants in the U.S.
In February 2021, the company announced that it intended to spin off its Spine and Dental businesses....
In February 2021, the company announced that it intended to spin off its Spine and Dental businesses....
The pandemic presented both of these firms with unique challenges. However, each has remained profitable and is well positioned to keep weathering the crisis—and to increasingly prosper as the economy reopens and rebounds. Meanwhile, their solid yields add appeal....
Goodyear’s longer-term outlook is positive as demand for its tires continues to recover. In addition, it’s making significant investments in future tire technologies, including for electric vehicles. But in the near term, it faces considerable inflationary pressures.
GOODYEAR TIRE & RUBBER, $14.08, is a buy. The manufacturer (Nasdaq symbol GT; TSINetwork Rating: Extra Risk) (www.goodyear.com; Shares outstanding: 281.8 million; Market cap: $3.7 billion; No dividends paid) expects inflationary cost pressures to push its expenses up by $700 million to $800 million in just the first half of this year compared to last year....
GOODYEAR TIRE & RUBBER, $14.08, is a buy. The manufacturer (Nasdaq symbol GT; TSINetwork Rating: Extra Risk) (www.goodyear.com; Shares outstanding: 281.8 million; Market cap: $3.7 billion; No dividends paid) expects inflationary cost pressures to push its expenses up by $700 million to $800 million in just the first half of this year compared to last year....
The coronavirus pandemic forced the cancellation of most vacation plans. However, the reopening of the economy is spurring strong demand for travel—and Wyndham should benefit from that surge. Meanwhile, Twilio prospered during the pandemic, but its share price has come down lately....
First, the good news: widening cannabis legalization will eventually lead to some great business successes. The bad news is that only a few of the multitude of cannabis stocks today will pay off for investors. Consumer cannabis demand is high, but growing and distributing it across multiple markets is more difficult....
We continue to see attractive investment opportunities for our subscribers in top drug stocks—and that includes AbbVie Inc. Over the years, meanwhile, we’ve found that spinoffs are about as close as you can get to a sure thing in investing. It’s one key reason why we think AbbVie, itself a spinoff, has further gains ahead for investors. We recommend this stock as a Power Buy.
ABBVIE INC., $156.05, is a buy. The company (New York symbol ABBV; TSINetwork Rating: Above Average) (www.abbvie.com; Shares outstanding: 1.8 billion; Market cap: $275.7 billion; Dividend yield: 3.6%) was formed on January 3, 2013, when Abbott Laboratories (symbol ABT on New York) split into two publicly traded companies.
Since its spinoff from Abbott Laboratories, AbbVie has depended heavily on its Humira drug to drive both its sales and earnings....
Barrick Gold offers you a great way to prosper from any rise in gold prices because of the war in Ukraine and the ongoing COVID-19 pandemic. If inflation keeps rising these next few years (a clear possibility), gold stocks will attract new interest to keep pushing up their prices....